Sushmita Panda
Pharma Reporter at Citeline
Pharma Reporter @PharmaScrip, @Citeline | Potterhead | Bibliophile | Alum: @acjindia | tip/lead: [email protected]
Articles
-
1 week ago |
insights.citeline.com | Sushmita Panda
In Brief: Neurocrine Details New Data For Schizophrenia Drug Moving To Phase III Targets Key Regulator Of Neurotransmitters Neurocrine reports new details of positive Phase II results in schizophrenia and a favorable safety and cardiovascular profile for its first-in-class oral M4 agonist, now moving to Phase III trials. Neurocrine Biosciences reports further details of Phase II findings for its novel schizophrenia candidate. • Source: Alamy
-
1 week ago |
insights.citeline.com | Sushmita Panda
In Brief: Nicox Extends Cash Runway As Kowa Advances NCX 470 In JapanH2 Start For Phase III TrialEye drug is already in Phase III trials elsewhere, with results due in Q3. Nicox could earn up to a further €24.5m in milestones and royalties from Kowa alliance. Kowa advances Nicox's ocular hypertension candidate in Japan (Shutterstock)
-
2 weeks ago |
insights.citeline.com | Sushmita Panda
In Brief: Tourmaline Reports Positive Topline Phase II Results for Pacibekitug In CKD Potential Expansion Into Additional IndicationsBased on first positive results for any quarterly IL-6 inhibitor, company plans to initiate Phase III cardiovascular outcomes trial. Promising topline Phase II results for Tourmaline's quarterly IL-6 inhibitor. (Shutterstock)
-
2 weeks ago |
insights.citeline.com | Sushmita Panda
In Brief: Essence Raises Ionis Tryngolza Hypertriglyceridemia Filing Hopes Olezarsen Met All Key Endpoints In Moderate HTG StudyTryngolza has met endpoints in a moderate hypertriglyceridemia trial. Positive results in severe disease in Q3 could allow for a filing for a broader patient population than its currently approved indication of familial chylomicronemia syndrome. Ionis logo. (Shutterstock)
-
3 weeks ago |
insights.citeline.com | Sushmita Panda
In Brief: Sanofi Commits $20bn To US R&D And Manufacturing By 2030US Almost Half Of Firm’s Q1 Revenue Move by French major aligns with broader industry efforts to localize production amid political pressure, as Trump pushes to onshore manufacturing and hints at easing tariff threats. Sanofi plans major new investments in US manufacturing and R&D • Source: Getty
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 4K
- Tweets
- 8K
- DMs Open
- Yes
RT @DrLahariya: There is no such thing as an "active case" in COVID-19. #COVID-19 is now a self-limiting illness, with nearly all cases m…
RT @TheLancet: 🧵1/ Presented at #ASCO25: New phase 3 trial suggests adding lurbinectedin to first-line treatment extends survival in exten…
RT @jarshadnk: People waking up to em-dashes and Oxford commas say that their usage is clear sign of AI writing. This is not true—the em da…